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ABSTRACT - Purpose: Delineate the selected pharmacodynamics of a naturally occurring stilbene 3’-
Hydroxypterostilbene. Objective: Characterize for the first time the pharmacodynamics bioactivity in several 
in-vitro assays with relevant roles in heart disease, inflammation, cancer, and diabetes etiology and 
pathophysiology. Methods: 3’-Hydroxypterostilbene was studied in in-vitro assays to identify possible 
bioactivity. Results: 3’-Hydroxypterostilbene demonstrated anti-oxidant, anti-inflammatory, cytotoxic, anti-
adipogenic, histone deacetylase, and sirtuin-1 inhibitory activity. Conclusions: The importance of 
understanding individual stilbene pharmacologic activities were delineated.  Small changes in chemical structure 
of stilbene compounds result in significant pharmacodynamic differences.  
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
__________________________________________________________________________________________ 
 
INTRODUCTION 
 
Studies on natural products continue to be evaluated 
for their therapeutic potential.  3’-
hydroypterostilbene, C16H16O4, MW 272.29 g/mol, 
is stilbene derived through the phenylpropanoid 
pathway that is an analogue of resveratrol, a 
compound very widely studied and available as a 
nutraceutical  (Figure 1).  
 Figure 1. Chemical Structure of 3'-Hydroxypterostilbene 
 
 
3’-Hydroxypterostilbene is structurally related to 
resveratrol, which is a well-studied natural product 
with associated health benefits. Reportedly, 3’-
hydropyterostilbene has been isolated from  
 
Sphaerophysa salsula, which is used in Chinese 
folk medicine to treat hypertention (1). 3’-
Hydroxypterostilbene was evaluated for its effects 
in-vitro and in-vivo against human cancer cell lines 
(COLO 205, HCT-116, and HT-29) and in nude 
mice (2). Researchers of this study found that 3’-
Hydroxypterostilbene induced apoptosis and 
autophagy to inhibit cell growth. Specifically, 
down-regulation of phosphatidylinositol 3-kinase 
and mitogen-activated protein kinase was observed. 
In the in-vivo model of the same study, researchers 
found that 3’-Hydroxypterostilbene was able to 
reduce tumor burden in nude mice bearing COLO 
205 tumor xenografts. Specifically, down-
regulation of cyclooxygenase-2, matrix 
metallopeptidase-9, vascular endothelial growth 
factor, and cyclin D1, and apoptosis was observed. 
Tolomeo et.al. evaluated 3’-Hydroxypterostilbene 
for its effects in sensitive and resistant leukemia 
cells (3). 3’-Hydroxypterostilbene was determined 
to be effective at inducing apoptosis in HL60 and  
_________________________________________ 
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HUT78 cells. Additionally, apoptosis was induced 
by 3’-Hydroxypterostilbene, in HUT78B1 and 
HUT78B3, Fas-ligand resistant lymphoma cell lines, 
and in HL60-R and K562-ADR, multi drug-
resistant leukemia cell lines. In this study it appears 
that 3’-Hydroxypterostilbene induces apoptosis 
through an intrinsic apoptotic pathway with no 
cytotoxic effects in normal hemopoietic stem cells. 
Biomedical literature appears to have only two 
published studies evaluating the pharmacodynamics 
of 3’-Hydroxypterostilbene. Both studies evaluated 
the anti-cancer effects in colon cancer or leukemia 
cells. The objective of the study was to characterize 
the effects of 3’-Hydroxypterostilbene in vitro. We 
wanted to replicate the anti-cancer effects 
previously reported, and evaluate 3’-
hydroypterostilbene for its potential as a therapeutic 
for metabolic disorders. With the growing number 
of metabolic disorders and use of natural products, 
new and effective therapies are of interest. Since the 
underlying causes of metabolic disorders are only in 
part delineated, with origins in inflammation and 
gene dysregulation, we take a multifaceted 
approach to assessing the therapeutic potential of 
3’-Hydroxypterostilbene. To our knowledge, this 
will be first study assessing the effects of 3’-
Hydroxypterostilbene in cancer cell lines of the 
liver and prostate, anti-oxidation, anti-adipogenesis, 
anti-inflammation, histone deacetylase HDAC), and 
sirtuin 1 (SIRT1) inhibitory activities. 
 
METHODS 
 
Chemicals and Reagents 
3’-Hydroxypterostilbene and pterostilbene were 
generously provided by the Sabinsa Corporation® 
(Piscataway, NJ, USA). Dimethyl sulfoxide 
(DMSO), trypsin-ethylenediamenetetraacetic acid 
(Trypsin-EDTA, Catalogue No. T4174), trypan blue, 
sodium bicarbonate, phosphate-buffered saline 
magnesium and calcium free (PBS), cell culture 
tested sodium carbonate, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), sodium 
pyruvate, Dulbecco’s Modified Eagle Medium 
(DMEM), McCoy’s 5A Medium, Minimum 
Essential Medium, RPMI 1640 medium (RPMI), 
and penicillin-streptomycin were purchased from 
Sigma-Aldrich® (St Louis, Missouri, USA). Alamar 
Blue® was purchased from Trek (Cleveland, OH, 
USA). Heat-inactivated fetal bovine serum (FBS) 
was purchased from Equitech-Bio Inc. (Kerrville, 
TX, USA). TPP, Sartdet, and BD Biosciences T25 
(5 mL), T75 (15 mL), and T125 (25 mL) flasks 
were purchased from Central Stores (Washington 
State University, Pullman, WA, USA) or VWR 
International (West Chester, PA, USA). Assay 
measurements using a microplate reader used a 
BioTek Synergy HT Multi-Mode Microplate 
Reader (Winooski, VT, USA) with Gen 5 software, 
unless otherwise indicated. 
3T3-L1 fibroblasts (murine fibroblasts), HCT-
116 (human colorectal carcinoma), Hep-G2 (human 
hepatocellular carcinoma), HT-29 (human 
colorectal adenocarcinoma), MDA-MB-231 (human 
estrogen receptor negative breast adenocarcinoma), 
and PC-3 (human prostate adenocarcinoma) were 
purchased from American Type Culture collection 
(ATCC, Manassa, VA, USA). 
The Adipogenesis (Catalog No. 10006908), 
Antioxidant (Catalog No. 709001), Cyclooxygenase 
Inhibitor Screening (Catalog No. 560131), Histone 
Deacetylase (HDAC) Activity (Catalog No. 
10011563), and SIRT1 Direct Fluorescent 
Screening (Catalog No. 10010401) Assay Kits were 
purchased from Cayman Chemical Company (Ann 
Arbor, MI, USA). Prostaglandin E2 Biotrak™ 
Direct Assay Kit (RPN222) was purchased from 
GE Healthcare Biosciences (Pittsburgh, PA, USA).   
 
XlogP Determinations 
The partition coefficient (XLogP) was 
experimentally investigated using the shake flask 
method at ambient temperature (23 ± 2°C) with 
spectrophotometric analysis (4-5) and by a HPLC 
analytical assay (6). 
For the shake flask method HPLC grade water 
and octanol were combined in a 2 L Erlenmeyer 
flask to saturate for 24 hours on a plate stirrer and 
allowed to separate for 24 hours. 3’-
Hydroxypterostilbene was evaluated at 
concentrations (5, 10, and 50 mg/33 mL) with 
varying volumes of the saturated water and octanol 
in proportions of 1:1, 2:1, and 1:2 (v/v). Mixtures 
were rotated 100 times to facilitate sufficient 
mixing. Samples were allowed to separate into 
octanol and water entities and isolated from each 
other. Standard curves (0-100 μg/mL) were 
prepared both in HPLC grade water and octanol. A 
reference sample of pterostilbene with a reported 
partition coefficient value of 3.8 (7) was also 
subjected to the same treatment as 3’-
Hydroxypterostilbene for comparison. All samples 
were assessed by spectroscopy in replicate (n = 3) 
and assayed in replicate (n = 4), with a peak 
absorbance at 325 nm. 
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When applying the analytical assay, samples 
were dried to completion using a SpeedVac® 
(Savant SC110 A SpeedVac® Plus Concentrator 
with Universal Vacuum System (UVS400), Savant 
Instruments, Inc, Holbrook, NY, USA).  Internal 
standard (4-methylumbelliferone, 0.10 mL) was 
added to the dried samples and dried to completion. 
Samples were resuspended in mobile phase (0.40 
mL), injected (0.05 mL) into the system, and the 
developed analytical method applied (6). The peak 
area ratios were determined for the octanol and 
aqueous phase taking into consideration the total 
volume of solvents for all standards and samples 
(8); concentrations of unknown samples were 
determined using linear regression from the 
standard curve and the XLogP was calculated. The 
retention time of 3’-Hydroxypterostilbene was 
notated and unweighted least squares linear 
regression applied to determine the XLogP for the 
unknown (8-11). 
 
Cytotoxic Activity 
Cell Culture 
All cell line culture conditions included temperature 
at 37°C, 5% CO2 atmosphere. All media used to 
maintain cell lines were prepared using suggested 
specification from the manufacturer, degassed, and 
filtered under aseptic conditions under a laminar 
flow hood.  HCT-116 and HT-29 were maintained 
in McCoy’s 5A Medium modified with 10% FBS, 
penicillin-streptomycin solution (10 mL/L), and 
HEPES (6.0 g/L). Hep-G2 was maintained in MEM 
with 10% FBS and penicillin-streptomycin solution 
(10 mL/L). MDA-MB-231 was maintained in 
DMEM with 10% FBS, penicillin-streptomycin 
solution (10 mL/L), HEPES (2.4 g/L), and sodium 
pyruvate (110.4 mg/L). PC-3 was maintained in 
RPMI modified with 10% FBS and penicillin-
streptomycin solution (10 mL/L).  
Cells were seeded after counting using a trypan 
blue assay to predetermined optimum cell density in 
a 96 well plate as to avoid over confluence on day 
one and returned to the incubator. On day two, cells 
were treated with fresh media with 3’-
Hydroxypterostilbene yielding final concentrations 
1-250 µg/mL dissolved in DMSO and returned to 
the incubator. 
 
Alamar Blue Assay 
On day five, cells underwent an Alamar Blue Assay 
(12). Briefly, treatment media was removed and 
replaced with 10% Alamar Blue in fresh media. 
Plates were returned to the incubator and brought to 
room temperature. This fluorescing product was 
quantified using a microplate reader with excitation 
set at 530 nm and emission set at 590 nm 
(Cytofluor® 4000 fluorescence multi-well plate 
reader, Applied Biosystems, USA). Modeling and 
analysis of data was carried out using WinNonlin® 
Version 5.2 and Microsoft® Excel. This assay is 
based on the ability of the live cells to reduce 
resazurin to resorufin thus producing a pink 
fluorescing product. 
 
Anti-oxidant Determination 
All reagents were prepared according to the 
manuscript provided with the Antioxidant Assay 
Kit (13). A 6-hydroxy,2,5,7,8-tetramethylchroman-
2-carboxylic acid (Trolox) standard was prepared at 
concentrations specified as this compound is a 
readily used marker of anti-oxidant activity. The 
assay as carried out to manufacturer specifications 
with 3’-Hydroxypterostilbene treatments at final 
concentrations of 1-250 µg/mL in DMSO evaluated 
for antioxidant capacity. The reaction was initiated 
with addition of hydrogen peroxide, incubated on 
an orbital shaker for 5 minutes at room temperature 
and read using a plate reader at 750 nm. Average 
values were calculated and graphed to the standard 
as absorbance versus Trolox concentration. 
Unknown sample anti-oxidant capacities were 
calculated using unweighted least squares linear 
regression. 
 
Anti-adipogenic Determination 
Cell Culture 
3T3-L1 fibroblasts were cultured in DMEM 
modified with 10% at 37°C, 5% CO2 atmosphere. 
Cells were seeded on day one in a 96 well plate at 
30,000 cells/well and grown to 75% confluence. All 
reagents were prepared according to manufacture 
recommendations (14). 3T3-L1s were chemically 
differentiated from fibroblast type cells into pre-
adipose cells to mature adipose cells after 
stimulation with isobutylmethylxanthine (IBMX), 
insulin, and dexamethasone (15-16). 
Dexamethasone is the primary adipogenic agent 
used in combination with IBMX and insulin have 
synergistic roles in adipogenesis (15, 17). These 
cells replicate even if not able to differentiate, thus 
there is a distinct difference in morphology between 
those cells experiencing cytotoxic effects versus 
those cells that are unable to differentiate due to 
polyphenol treatment. On day three, growth 
medium was changed to induction medium [DMEM 
modified with 10% FBS, IBMX, insulin, 
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dexamethasone, and 3’-Hydroxypterostilbene]. On 
day six, induction medium was changed to insulin 
medium [DMEM modified with 10% FBS with 3’-
Hydroxypterostilbene]. Media was refreshed on day 
eight. Treatment with 3’-Hydroxypterostilbene was 
carried out at concentrations of 1-250 µg/mL. On 
day ten, quantification of lipid droplet was assessed 
using Oil Red O. Reagents were prepared following 
manufacturer instructions. After extraction of Oil 
Red O from lipid droplets, quantification of lipid 
accumulation was accomplished by using a 
microplate at 520 nm based on the premise that a 
proportional increase in lipid accumulation and 
absorbance exists.  
 
Anti-inflammatory Determination 
Cyclooxygenase Inhibition 
The three day COX Inhibitor Screening Assay Kit 
is used to identify COX-1 and/or COX-2 inhibitors 
(18). All reagents were prepared to manufacturer 
specifications and carried out accordingly. 3’-
Hydroxypterostilbene was prepared over the 
concentration range of 1-250 µg/mL in DMSO. 
Ibuprofen and etodolac or deracoxib, NSAID and 
COX-2 specific inhibitors, respectively, were used 
as controls. The assay was assessed with a plate 
reader at 420 nm within 10 minutes using the plate 
reader. Optical density for standards and samples 
were calculated with the percent bound (%B/B0). 
A %B/B0 versus log concentration 4-parameter 
logistic curve fit was used to determine the amount 
of PGs in each sample.  
 
In-Vitro Inflammatory Bowel Disease 
HT-29 cells were cultured and seeded in 96 well 
plates at a cell density of 10,000 cells per well and 
grown to ~80% confluence at 37°C, 5% CO2 
atmosphere. At confluence, cells were serum 
starved. After 24 hours, treatment groups with 3’-
Hydroxypterostilbene (1-250 µg/mL in DMSO) 
either with TNF-α (20 ng/mL) or without TNF-α 
was dissolved in media with serum (treatment 
media). Treatment was carried out at 37°C with 5% 
CO2 atmosphere for 24 hours. Medium was 
collected the following day and stored at -80°C 
until further analysis using a commercially 
available ELISA kit. Prostaglandin E2 Biotrak™ 
Direct Assay Kit was utilized to indirectly quantify 
PGE2 synthesis. The assay is based on the 
competition between PGE2 and PGE2–peroxidase to 
the limited amount of binding sites on the plate. All 
reagents were prepared and carried out according to 
the manufacturer instructions provided with the kit 
(19). Preliminary detection of PGE2 was assessed at 
630 nm and at 450 nm within 10 minutes with a 
plate reader. Optical density for each standard and 
samples was calculated and the percent bound 
(%B/B0) was determined. A %B/B0 versus 
logarithmic PGE2 concentration from the standards 
linear regression curve fit was used to determine the 
amount of PGs in each sample. 
 
Histone Deacetylase (HDAC) Activity 
All reagents were prepared according to the 
manufacturer instructions provided with the HDAC 
Activity Assay Kit (20). An acetylated substrate 
was incubated with 3’-hydroxypterostilbene alone 
or 3’-Hydroxypterostilbene with Trichostatin A 
(known HDAC inhibitor readily used as a 
reference) at specified concentrations (1-100 
µg/mL). If the compound of interest is a HDAC 
inhibitor, the sensitized substrate decreases in 
fluorescence when treated with the HDAC 
developer. This assay was read at an excitation 
wavelength of 360 nm and an emission wavelength 
of 460 nm to quantify HDAC activity. A linear 
association was established by fluorescence versus 
deacetylated standard from for each sample. HDAC 
activity was determined accounting for dilution, as 
one unit is defined as the amount of enzyme leading 
to the formation of 1.0 nmol of deacetylated 
compound per minute at 37°C.   
 
Sirtuin 1 inhibitory Activity 
All reagents were prepared according to the 
manuscript provided with the SIRT1 Direct 
Florescent Screening Assay Kit (21). In this assay 
the p53 sequence was incubated with SIRT1 
(enzyme), cosubstrate (NAD+), and 3’-
Hydroxypterostilbene (1-250 µg/mL). The 
inhibitory activity was monitored using a 
fluorescence-based assay to screen for inhibitors or 
activators by quantification of the sensitized 
deacetylated substrate. The amount of deaceylation 
is proportional to the amount of fluorescence, which 
was able to determine if the compound is an 
inhibitor or an activator. The activity of the selected 
compounds can be compared to sirtinol, a known 
inhibitor (21) or to resveratrol, a known activator 
(22). Plates were read with excitation (350 nm) and 
emission (460 nm) for this fluorescence-based assay. 
The average fluorescence for each sample was 
determined and the percent ratio of inhibition to 
activation was calculated; thus a negative number 
indicated activation of SIRT1.  
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STATISTICAL ANALYSIS 
 
Data were compiled and presented as mean ± 
standard deviation (SD) or mean ± standard error of 
the mean (S.E.M.) where appropriate. Where 
possible, WinNonlin 5.2 modeling software was 
used to determine statistical significance and 
inhibitory concentration values. A two tailed, 
unpaired t-test was used to compare controls to 
treatments. Significance was noted p-values <0.05. 
Generally, significance from negative controls are 
indicated as * p<0.05, ** p<0.01, and *** p<0.005. 
Significance from positive controls are indicated as 
# p<0.05, ## p<0.01, and ### p<0.001.  
 
RESULTS 
 
XlogP Determinations 
Experimental values were compared to a computer 
generated CLogP value using New ClogP 
Calculator, (University of Massachusetts at Boston 
General Biology Website, 
http://intro.bio.umb.edu/111-
112/OLLM/111F98/newclogp.html, Boston, MA, 
USA).   
The reference sample, pterostilbene, has a 
reported partition coefficient of 3.8 and 4.1 (7, 23). 
The CLogP for pterostilbene that was generated has 
a value of 3.69. The ADMET Predictor™ 
Moriguchi model of predicted partition coefficient 
was 2.91 for pterostilbene. According to Sabinsa® 
from whom we have obtained 3’-
Hydroxypterostilbene, a LogD value of 3.36 is 
reported. The CLogP generated from the computer 
program determined that 3’-Hydroxypterostilbene 
has a CLogP of 3.39 ( 
Figure 2). The ADMET Predictor™ Moriguchi 
model of predicted partition coefficient generated a 
value of 2.88 for 3’-Hydroxypterostilbene.  
A three-parameter polynomial model was used 
to describe standard curves and unknown 
concentrations were calculated for each sample. 
This model was statistically a significantly better fit 
as determined from an F-test. The partition 
coefficient was determined from the logarithmic 
ratio of the concentration of octanol to water, 
adjusting for dilution and volume. The octanol and 
methanol p-values are 1.044E-20 and 0.047, 
respectively. Another objective assessment to grade 
the models to determine which model fits the 
experimental data best is Akaike Information 
Criterion (AIC) (24). In this assessment the lower 
the AIC value the better. The AIC values for the 
linear and quadratic models were lower for the 
quadratic models. For the pterostilbene the average 
quadratic function for the standard curve for 
pterostilbene in octanol can be described as y = 
7.45x2 + 28.43x – 14.65 and in water can be 
described as y = -2.58x2 + 58.63x – 18.92; 
respectively the average correlation coefficients are 
0.99 and 0.99. The average quadratic function for 
the standard curve for 3’-Hydroxypterostilbene in 
octanol can be described as y = -4.10x2 + 66.10x – 
24.05 and in water can be described as y = -21.93x2 
+ 84.61x – 24.55; respectively the average 
correlation coefficients are 0.99 and 0.99. The 
experimental XLogP was determined to be 3.18. 
Using linear regression the LogD was determined to 
be 2.78. Experimentally, pterostilbene has a 
partition coefficient of 3.57. 
Through this study the developed analytical 
method was successful. Differences in retention 
times were observed between 4-
methylumbelliferone (6 minutes), 3’-
Hydroxypterostilbene (15 minutes) and 
pterostilbene (26 minutes). The partition co-
efficient for 4-methylumbelliferone is reported as 
1.9 (25).  A relationship between retention time and 
LogD (R2 = 0.98) was established which can be 
described as retention time = 10.44 (LogD) - 13.248. 
 
Cytotoxicity – alamar blue assay 
Cell viability assays often evaluate the percentage 
of cell survival. No significant differences were 
detected from untreated human controls over the 
screening concentration range; therefore, anticancer 
activities are evaluated.  3T3-L1 was included for 
the lipogenesis study. No significant differences 
were observed. 3’-Hydroxypterostilbene had an 
established concentration-dependent cytotoxic 
effect on the cell lines evaluated ( 
 
 
 
	
Figure 3). The IC50 values for HCT 116, MDA-MB-
231, PC-3, and HEPG2 are 7.62 ± 0.19 µg/mL, 
18.06 ± 6.8 µg/mL, 23.29 ± 8.48 µg/mL, and 8.38 ± 
0.00 µg/mL, respectively.  
 
Antioxidant Activity  
Assays that can be used to measure anti-oxidant 
activity include chemiluminescence, cell 
morphology, and carbon monoxide production (26-
27). The Folin-Ciocalteu assay measures total 
phenolics in a sample and after, has a strong 
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correlation with DPPH radical scavenging activity 
(28). Alternatively, in this study antioxidant 
capacity of 3’-Hydroxypterostilbene was measured 
by the Trolox equivalent anti-oxidant capacity assay 
(27). The principle behind this method is the 
formation of the ferryl myoglobin (oxygen carrying 
protein) radical from metmyoglobin (oxidized form 
of myoglobin) and hydrogen peroxide, which 
converts the phenothiazine compound ABTS to 
produce a radical cation (26, 29). In the presence of 
anti-oxidants in the sample, oxidation of ABTS to 
ABTS•+ by metmyoglobin is inhibited. The resulting 
chromogen has a peak absorption of 645-815 nm. 
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Figure 2. CLogP Values. The calculated partition coefficient of (A) 3’-Hydroxypterostilbene and reference sample (B) 
pterostilbene using the NewClogP Calculator.  (ADD SHORT DESCRIPTION OF THIS DIAGRAM) 
	 	 
 
 
 
	
Figure 3. Cytotoxicity of 3'-Hydroxypterostilbene. HCT 116: human colorectal carcinoma; MDA-MB-231: human 
breast adenocarcinoma, PC-3: human prostate adenocarcinoma, HEPG2: human hepatocellular carcinoma, 3T3L1: 
(normal murine fibroblasts). Data is expressed as mean ± SEM, n = 4. 
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	Figure 4. Anti-oxidant Activity of 3'-Hydroxypterostilbene in Trolox Equivalents (µg/mL). Data are presented as mean ± 
SD, n=2-3. Significance from negative controls are noted as ** p<0.01 and *** p<0.005. 
Vehicle (DMSO) only samples had a low anti-
oxidant capacity (0.14 mM ± 0.006). 3’-
Hydroxypterostilbene has a concentration-
dependent anti-oxidant activity over the 
concentration range. Significant differences were 
observed at 50 and 100 µg/mL from controls. 
Treatment at 250 µg/mL approached significance 
(p=0.058).  At 10 µg/mL or 54.16 µg/mL (0.22 
mM) Trolox equivalents of 3’-
Hydroxypterostilbene indicates a 5-fold greater 
anti-oxidant capacity than the gold standard Trolox 
(Figure 4). However, at higher concentrations (100 
and 250 µg/mL) 3’-Hydroxypterostilbene is equal 
to or less than comparable levels of Trolox (100.2 
and 129.88 µg/mL, respectively). 
	
Anti-adipogenic Activity  
Cytotoxicity of 3-Hydroxypterostilbene was 
evaluated with no significant differences detected.  
In this assay, the negative control (Ctl) consisted of 
cells chemically differentiated and maintained, and 
modified with the vehicle (DMSO), which was 
considered to represent 100% differentiation and 
lipid accumulation. Genistein, the positive control, 
is an isoflavonoid known to have anti-adipogenic 
properties. Genistein was able to reduce 
adipogenesis at all concentrations evaluated. 3’-
Hydroxypterostilbene did not appear to have a well-
established concentration-effect relationship over 
the concentration range assessed ( 
 
 
 
 
 
Figure 5), although there appears to be a reduction 
of induced adipogenesis over all concentrations 
assessed. The 50 and 100 μg/mL concentrations 
were able to significantly reduce adipogenesis 
compared to negative control. There were no 
significant differences between genestein and 3’-
Hydroxypterostilbene at comparable concentrations. 
Treatment at 250 µg/mL approached significance 
(p=0.052). 
 
Anti-inflammatory Activity 
Inflammation is the direct reaction to stimuli, in 
which immunomodulators such as cyclooxygenases, 
prostaglandins (PG), prostacyclins, thromboxanes, 
leukotrienes, and lipoxygenases mediate the body’s 
response. Immunomodulator synthesis are inhibited 
by non-steroidal anti-inflammatory drugs (NSAIDs), 
steroids, receptor level antagonists, and 
lipoxygenase inhibitors (33).  
 
0 
20 
40 
60 
80 
100 
120 
140 
160 
Vehicle 1 10 50 100 250 
Tro
lox
 eq
uiv
ale
nts
 (µ
g/m
L) 
Concentration (µg/mL) 
Anti-oxidant Activity 
*** 
** 
J Pharm Pharm Sci (www.cspsCanada.org) 18(5) xxx - xxx, 2015 
 
	
721 
 
  
 
 
 
 
 
Figure 5. Anti-Adipogenic Activity of 3'-Hydroxypterostilbene. Data is expressed as mean ± S.E.M., n=4. Significance 
from negative controls are noted as * p<0.05 and ** p<0.01.  
Cyclooxygenase 1 and Cyclooxygenase 2 
Inhibition 
Cyclooxygenases are enzymes that are involved 
with the synthesis of prostaglandins, thromboxanes, 
and prostacyclins. 3’-Hydroxypterostilbene 
demonstrates both COX-1 and -2 inhibitory 
activities in a dose independent manner (Figure 6). 
For COX-1 activity, 3’-Hydroxypterostilbene (1, 10, 
and 250 μg/mL) had p-values that approached 
significance (p=0.08). Ibuprofen demonstrated a 
concentration dependent inhibition. Statistically 
significant differences were observed only in COX-
1 inhibition at concentration of 10 μg/mL compared 
to ibuprofen at 250 μg/mL. Compared to ibuprofen, 
3’-Hydroxypterostilbene appeared to have better 
COX-1 inhibition. COX-2 inhibition after treatment 
with 3’-Hydroxypterostilbene approached 
significance at 10 and 250 μg/mL, p=0.051 and 
0.054, respectively. However, 1 μg/mL treatment of 
3’-hydroxtyperostilbene was significantly different 
from controls (p=0.037). The only significant 
difference between the positive control (deracoxib) 
and 3’-hydroxtyperostilbene was at 1 μg/mL 
(p<0.001).  
 
In-Vitro Inflammatory Bowel Disease 
3’-Hydroxypterostilbene did not appear to have a 
concentration-effect relationship after induction of 
inflammation as quantified by the synthesis of 
PGE2 ( 
 
 
 
 
Figure 7). 3’-Hydroxypterostilbene did not induce 
inflammation nor disrupt basal levels of PGE2 
synthesis to a statistically significant extent from 
controls. The inhibitory effects of 3’-
Hydroxypterostilbene was most apparent at 1 
µg/mL but was reduced at all concentrations; 
although not significantly different from 
dexamethasone. A dose dependent effect was 
observed after treatments of 10 µg/mL. 
Dexamethasone did have an effect in reducing 
inflammation but did not appear to be in a dose 
dependent manner.  
 
Histone Deacetylase Activity 
A value below the control, Trichostatin A, a known 
HDAC inhibitor, indicates a reduction in HDAC 
activity indicating HDAC inhibition. Values above 
this control indicate activation of HDAC activity, as 
an increase in HDAC activity. 3’-
J Pharm Pharm Sci (www.cspsCanada.org) 18(5) xxx - xxx, 2015 
 
	
722 
Hydroxypterostilbene inhibited the activity of 
HDAC and reduces HDAC activity compared to 
control; as such a HDAC inhibitor ( 
 
 
 
 
 
Figure 8). There was a significant different between 
control (DMSO) and 50 µg/mL.   
 
 
 
	  	
Figure 6. Cyclooxygenase Inhibition by 3'-Hydroxypterostilbene. (A) COX-1 and (B) COX-2 inhibitory activity of 3’-
Hydroxypterostilbene. Data are presented as a mean ± S.E.M., n = 4. Significance from negative control is noted as * 
p<0.05. Significance from positive control is noted as ### p<0.001. 
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Figure 7. PGE2 Synthesis. Amount of PGE2 synthesized after no induction and induction with TNF-α and treatment with 
and without 3’-Hydroxypterostilbene compared to dexamethasone.  Data are presented as a mean ± S.E.M., n = 4. 
Significance from negative controls are expressed as * p<0.05 and ** p<0.01.  Significance from positive controls are 
expressed as # p<0.05. 
 
  
 
 
 
 
 
Figure 8. HDAC Activity. Data are presented as mean ± S.E.M., n=3. Significance from negative control is indicated as * 
p<0.05. 
 Figure 9. SIRT1 Inhibition. Data are presented as a mean ± S.E.M., n = 3. 
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Sirtuin 1 Inhibitory Activity.  
3’-Hydroxypterostilbene acted as both an activator 
at mid-concentrations (10 and 50 µg/mL) evaluated 
and also an inhibitor at the lower (1 µg/mL) and 
upper (100 µg/mL) concentrations evaluated 
(Figure 9). The change of resveratrol from an 
activator to an inhibitor at higher concentrations 
(100 and 250 µg/mL) may be due to inherent 
properties of resveratrol as an unstable molecule 
and/or problems with solubility or a complex 
concentration-effect relationship. 
 
DISCUSSION 
 
It is likely that some of the pharmacodynamic 
responses are directly related to the structure of 3’-
Hydroxypterostilbene. The New ClogP program 
uses an algorithm including the chemical moieties 
of the compound to determine the CLogP.  Using 
the ADMET Predictor™ Version 5.0 the Moriguchi 
model of predicted partition coefficient was also 
employed. A disadvantage to this method is that it 
is an endpoint measurement not a thermodynamic 
measurement.  The XLogP was assessed through 
the use of three different methods and determined to 
be relatively comparable with the values utilizing 
predictive programs and from cited sources. The 
partition coefficient of the reference pterostilbene 
was 2.91-3.69 and 3’-Hydroxypterostilbene ranged 
from 2.88-3.39. In particular, from the experimental 
data a true thermodynamic octanol-water partition 
coefficient is determined which is a major 
advantage to the HPLC assay. As an alternative, a 
library of samples with known partition coefficients 
can be assayed using the developed method for 3’-
Hydroxypterostilbene. A LogP-retention time plot 
can be generated to form a linear relationship. A 
pattern emerged indicating a decreased lipophilicity 
of 3’-Hydroxypterostilbene compared to the 
reference, which was supported by the application 
of the developed analytical method with an earlier 
retention time. Having lipophilic properties may 
have played a role in activities with regards to 
solubility and permeability.  
In our cytotoxic studies we were able to 
reproduce similar results as other researchers (3). 
3’-Hydroxypterostilbene appeared to have the 
greatest effects in prostate cancer cell line, PC-3. 
Structural features of polyphenols that have been 
associated with enhancing anti-oxidant capacity 
include the presence of a 3-hydroxyl group on the 
-ring and/or a hydroxyl group on the C3 position. 
A single 3’-hydroxyl group on the B-ring and a 
saturated heterocyclic C-ring has been suggested as 
being causes of reduced anti-oxidant capacity (27).  
3’-Hydroxypterostilbene appeared to have 
concentration-dependent anti-oxidant activity 
greater than that of Trolox. Anti-oxidant capacity of 
3’-Hydroxypterostilbene, reported here for the first 
time. At lower concentrations (1, 10, and 50 
µg/mL), 3’-Hydroxypterostilbene prevents 
oxidation at better levels than Trolox does but is 
reduced with an increase in concentration. Through 
this investigation it is evident that the selected 
polyphenols maintain their anti-oxidant activity like 
several other related stilbenes, in spite of small 
structural modifications. It is speculated that an 
increase in hydroxyl groups can increase the anti-
oxidant capacity. As a variety of diseases are 
associated with an imbalance of oxidants/anti-
oxidants, 3’-Hydroxypterostilbene may aid in 
restoration of a balance.  
Concentrations of 3’-Hydroxypterostilbene 
were comparable to genistein in reducing 
adipogenesis. At the two highest concentrations it is 
possible that solubility may have been an issue as 
there was a decrease in anti-adipogenic activity by 
3’-Hydroxypterostilbene. The lipophilicity may 
have played a role in the uptake of 3’-
Hydroxypterostilbene by cells for anti-adipogenic 
activity. It appears that 3’-Hydroxypterostilbene 
was most effective at inhibiting adipogenesis at 50 
µg/mL. Future studies warrant a closer look at 3’-
Hydoxypterostilbene along with selected 
polyphenols and its effect on reducing obesity.  
The expression of COX varies from tissue to 
tissue. COX-1 is involved in normal cell 
functioning typically involving mucosal integrity, 
while COX-2 is expressed after being induced by 
mitogenic stimuli (phorbol esters, 
lipopolysaccharides, and cytokines), suggesting 
involvement with neoplastic and inflammatory 
conditions (34). Due to COX-2’s role in the 
biosynthesis of PGs under acute inflammatory 
conditions, COX-2 is the target of NSAIDs and 
COX-2 inhibitors. Because of various 
complications with current treatments, an 
alternative agent for COX mediated inflammation is 
necessary, making phytotherapeutic agents like 
polyphenols potentially attractive alternatives. A 
reduction in inflammation can be helpful in 
reducing certain cancers and cardiopulmonary 
diseases and other chronic conditions (35). In 
particular, it appears that 3’-Hydoxypterostilbene 
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was effective at inhibiting both COX-1 and -2.  In 
future studies it would be prudent to take a closer 
look at the effects at concentrations lower than 1 
µg/mL to establish a concentration-effect 
relationship. It is possible that there are structural 
features of 3’-Hydoxypterostilbene that competes 
with cyclooxygenases to reduce inflammation. 
Inhibition of PGE2 synthesis appears to be an 
attractive target for management of cancer and 
inflammation. Oxidative stress is of clinical 
importance not only because oxidants are common 
in inflammation, but also because of disruption of 
mitochondrial energy metabolism. This disruption 
can lead to a breach of the gastrointestinal barrier 
function, which can cause mucosal barrier 
permeability and lead to the initiation and/or 
perturbation of mucosal inflammation. Disturbance 
of colonocytes may also impair the ability to 
combat free oxygen radicals responsible for cell 
damage involved in colitis.  Current drug therapies 
including 5-aminosalicyclic acid, corticosteroids, 
and immunomodulators, at times exacerbate the 
patient’s disease (36-37). These therapies and 
surgery can have significant side effects and 
morbidity. There is a current need for new and/or 
adjunctive treatments to effectively manage these 
diseases without these side effects. Vitamins and 
other micronutrients, including polyphenols 
involved in nutrient metabolism and modulation of 
oxidative stress (anti-oxidants), have demonstrated 
importance because of their protective roles in the 
prevention and treatment of nutrient deficiencies 
and in the amelioration of disease activity in 
individuals with IBD (38-39). Data from this study 
suggests that it is possible that 3’-
Hydoxypterostilbene can aid in reducing colitis by 
reducing inflammation and help maintain lowered 
levels of oxidative stress.   
Histone acetylases (HATs) are enzymes that 
acetylate histones on lysine residues. In conjunction, 
histone deacetylases (HDAC) are enzymes that can 
remove excess acetyl groups primarily histone 
lysine residues. If the balance of HAT and HDAC 
activity is left unchecked negative long term affects 
may result, affecting transcription by over 
condensing chromatin and repressing the 
transcription process thereby affecting normal gene 
expression, thus implying roles in diseases like 
cancer and inflammatory diseases (20, 40-42). 
Sirtuins are protein deacetylases dependent on 
nicotinamide adenine dinucleotide (NAD+) or class 
III HDACs but are structurally different from class I 
and II HDACs as the catalytic domain requires the 
use of NAD as a cofactor (22, 42). Sirtuin 1 
(SIRT1) activity is of particular interest as there is 
abundant information on the roles in regulation 
and/or control of metabolic activity, 
neurodegenerative diseases, and cell proliferation 
(22, 43-45). In an in-vitro model, SIRT1 regulated 
adipocyte and triglyceride accumulation, thus 
attenuating adipogenesis and increased lipolysis 
(44). 
This study serves to investigate the action of 3’-
Hydoxypterostilbene on HDAC and SIRT 1 activity. 
It was determined that 3’-Hydroxypterostilbene acts 
as an inhibitor of HDAC. Stilbenes could be 
activators or inhibitors. In this case, 3’-
Hydroxypterostilbene acted as both an activator and 
an inhibitor of SIRT1 depending on concentration 
levels.  This suggests that 3’-Hydoxypterostilbene 
may be further evaluated for its role in maintaining 
energy for mitochondrial and/or metabolic diseases 
as an activator at lower concentrations. While at 
higher concentrations, 3’-Hydroxypterostilbene 
may be more suitable as an inhibitor in the 
prevention and/or treatment of cancers, 
cardiovascular, and pulmonary diseases through 
promotion of apoptosis and/or autophagy, which is 
in-line with previous studies from Cheng et. al.(2); 
where titrating to appropriate concentration would 
be require. 
 
CONCLUSIONS 
 
In summary, 3’-Hydroxypterostilbene was 
demonstrated to have anti-adipogenic, anti-
inflammatory, anti-oxidant, HDAC, and SIRT1 
inhibitory activity for the first time. Collectively, 
the increased anti-oxidant, anti-adipogenic activity, 
cell selectivity and COX-2 specificity of 3’-
Hydroxypterostilbene is in support of its activity in 
prevention of cardiovascular and pulmonary 
diseases.  Coupled with HDAC and SIRT1 activity, 
3’-Hydroxypterostilbene demonstrates protective 
effects from neurodegenerative diseases and select 
cancers. Further pharmacodynamic investigations 
of 3’-Hydroxypterostilbene in inhibition of 
adipogenesis, inflammation, and SIRT1 are 
underway based on these preliminary investigations. 
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